Nuvo Research Inc. is a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10.

Nuvo's first commercialized pain product is Pennsaid®, a non-steroidal anti-inflammatory drug (NSAID), used to treat the signs and symptoms of osteoarthritis of the knee.  Pennsaid is available by prescription in the United States, Canada and several European countries.  Through the acquisition of ZARS Pharma, Inc. in May 2011, the Company broadened its pain portfolio with two approved products - Pliaglis® and Synera®.